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ABSTRACT 
Caffeine metabolites in wastewater were investigated as potential biomarkers for 
assessing caffeine intake in a population. The main human urinary metabolites of caffeine 
were measured in the urban wastewater of ten European cities and the metabolic profiles in 
wastewater were compared with the human urinary excretion profile. A good match was 
found for 1,7-dimethyluric acid, an exclusive caffeine metabolite, suggesting that might be a 
suitable biomarker in wastewater for assessing population-level caffeine consumption. A 
correction factor was developed considering the percentage of excretion of this metabolite in 
humans, according to published pharmacokinetic studies. Daily caffeine intake estimated 
from wastewater analysis was compared with the average daily intake calculated from the 
average amount of coffee consumed by country per capita. Good agreement was found in 
some cities but further information is needed to standardize this approach. Wastewater 
analysis proved useful to providing additional local information on caffeine use. 
 
Key words: Caffeine; 1,7-dimethyluric acid; back-calculation; correction factor; wastewater-
based epidemiology; urinary biomarkers 
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1. INTRODUCTION 
History suggests that caffeine has been used, in one form or another, since ancient 
times. In 2737 BC a Chinese Emperor used the leaves from a nearby bush to prepare a tea 
(Arab and Blumberg, 2008; Heckman et al., 2010). An old legend dates the use of coffee to 
the 9th century in the southern tip of the Arabian Peninsula when a shepherd noted euphoria 
and stimulating effects on his goats caused by eating wild coffee berries. He then decided to 
try them himself. Coffee later crossed to Africa and in the 1600s reached Europe becoming, 
over the centuries, the most commonly consumed beverage worldwide after water (Butt and 
Tauseef, 2011). 
Caffeine is a naturally occurring alkaloid found in beans, leaves and fruits of more 
than 60 plant species. The world’s main sources are coffee beans (Coffea arabica and Coffea 
robusta) and tea leaves (Camellia siniensis). It is also naturally found in kola nuts (Cola 
acuminate), cocao beans (Theobroma cacao), yerba mate (Ilex paraguariensis) and guarana 
berries (Paullinia cupana). Most caffeine is consumed with beverages such as coffee, tea and 
soft drinks (including “energy drinks”), while products containing cocoa or chocolate, and 
medications such as some analgesic formulations and dietary supplements contribute small 
amounts to the diet (Heckman et al., 2010). Total daily intakes vary throughout the world 
although coffee usually contributes significantly more than other drinks to overall caffeine 
consumption (coffee 71%, soft drinks 16% and tea 12%), particularly among adults 
(Heckman et al., 2010; Mitchell et al., 2014). Carbonated Soft drinks are the main source of 
caffeine for children (Mitchell et al., 2014).  
Chocolate contains on average around 1.3% of theobromine, 0.75% of caffeine and 
theophylline in small amounts; cola nut between 2 and 3.5% of caffeine, theobromine 
(between 1 and 3.5%) and small amounts of theophylline, and tea leaves around 3% of 
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caffeine (theophylline and theobromine in small amounts). This results in around 40-80 mg of 
caffeine per cup of tea (150 mL) while caffeine content in cocoa commercial products ranges 
from 2 to 7 mg (Barone and Roberts, 1996) and 5-20 mg/100 g in chocolate candy products. 
In soft drinks, variable levels of caffeine have been reported depending on the brand but the 
typical content is around 40 mg/360 mL (Chou and Bell, 2007). All these products contain 
relatively little caffeine compared to the average content of a coffee cup (60-150 mg/150 mL).  
Caffeine is extensively metabolized by the human liver to form three major 
metabolites by demethylation: 3,7-dimethylxanthine (known as theobromine), 1,7-
dimethylxanthine (paraxanthine) and 1,3-dimethylxanthine (theophylline). These are then 
broken down further in the liver by additional demethylation and oxidation and are excreted 
mostly in the urine (Heckman et al., 2010).  
While there is no specific recommendation for human caffeine intake, it is considered 
that average consumption of approximately 300 mg/day is not associated with adverse health 
effects (Fitt et al., 2013; Higdon and Frei, 2006). However, data about caffeine intake in the 
population are scarce. Caffeine consumption is usually assessed by dietary surveys, but 
getting accurate information in this way presents many limitations. For instance, subjects may 
under-report their caffeine intake when food diaries are completed or information is missing 
about the strength, brand or amount of caffeine product they have consumed, which may 
greatly affect the intake.  Another limitation is that in caffeine dietary surveys the subjects are 
usually asked about the consumption of certain beverages (mainly coffee and tea) but other 
products containing caffeine are not considered: for example, analgesics can contain as much 
as 200 mg caffeine per tablet (Derbyshire and Abdula, 2008). Another limitation for 
estimating the total caffeine intake is that the caffeine content of various drinks, food and 
dietary supplements is only known in some countries such as the USA (Fitt et al., 2013).  
6 
 
A complementary method would be to estimate consumption in the general population 
by using the levels of caffeine and its metabolites measured in urban wastewater as 
biomarkers of intake. This approach, called wastewater-based epidemiology (WBE), has been 
mainly applied in the last decade for estimating illicit drug consumption (Baker et al., 2014; 
Ort et al., 2014; Thomas et al., 2012; Zuccato et al., 2008) and more recently has also been 
proposed for the quantitative measurement of lifestyle habits such as tobacco and alcohol use, 
exposure to environmental and food contaminants or factors related to health and illness in a 
community (Lopes et al., 2014; Reid et al., 2011; Rodríguez-Álvarez et al., 2015; Rousis et 
al., 2017; Thomas and Reid, 2011; Yang et al., 2015). The main advantage of WBE is that it 
provides objective, up-to-date information about the use of these substances in a population 
and can therefore complement current epidemiological methods. 
In this study, the presence of caffeine and some selected metabolites was assessed in 
untreated wastewater in ten European cities. Levels in wastewater were compared with those 
measured in urine and with the human excretion profiles of caffeine reported in the literature 
in order to correlate the results from the different sources. 1,7-dimethyluric acid, an exclusive 
caffeine metabolite, was selected for estimating collective caffeine consumption. The 
reliability of this compound for caffeine back-calculation was evaluated by comparing the 
amounts measured by wastewater analysis with the average amount of coffee consumed in 
each country per capita. 
 
2. MATERIALS AND METHODS 
2.1  Chemicals and reagents 
Caffeine (1,3,7-trimethlxanthine), paraxanthine and 1-methylxanthine were purchased 
from Sigma Aldrich (St. Louis, MO, USA); 1-methyluric acid, 1,7-dimethyluric acid 7-
methylxanthine were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, California, 
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USA). Standard solutions at 1 mg/mL were prepared in methanol, except for 1-
methylxanthine, 7-methylxanthine, paraxanthine and 1,7-dimethyluric acid which were 
prepared in methanol-water (50/50) at pH 8.5-10 (adjusted with 25% ammonia to enhance 
solubility). A mix of all compounds at 10 ng/µL was prepared in methanol and then diluted to 
1.0, 0.1 and 0.01 ng/µL. Isotopically labeled compounds were caffeine-13C3 purchased from 
Sigma Aldrich and 1,7-dimethyluric acid-d3 from Santa Cruz Biotechnology. Labeled internal 
solutions were prepared separately.  Internal standard mixtures with 1 ng/µL of caffeine-13C3 
and 10 ng/µL of 1,7-dimethyluric acid-d3 were used as surrogates.  
All solvents were of reagent grade or higher. Methanol for pesticide analysis and 
ammonium acetate were from Carlo Erba Reagents (Italy). Ammonium hydroxide solution 
(25%) was acquired from Fluka (Buchs, Switzerland). LC-MS grade acetonitrile and 
hydrochloric acid (37%) were supplied by Riedel de Haen (Seelze, Germany). Water was 
purified using Milli-RO Plus 90 apparatus (Millipore, Molsheim, France). Solid-phase 
cartridges (3 mL Oasis HLB, 60 mg) and HPLC XTerra C18 column (3.5 μm, 1 mm × 100 
mm) were obtained from Waters Corp., Milford, MA, USA. 
 
2.2 Wastewater samples 
24-hour composite influent wastewater samples were collected from ten wastewater 
treatment plants (WWTP) in different European cities: Bristol (UK), Brussels (Belgium), 
Castellón (Spain), Copenhagen (Denmark), Lugano (Switzerland), Milan (Italy), Oslo 
(Norway), Porto (Portugal), Utrecht (Netherlands) and Zurich (Switzerland) (Table S2). 
Samples were collected daily for seven consecutive days in March 2015 and April 2015 
(Porto), frozen immediately after collection to prevent degradation of the compounds and sent 
to Milan within 24 hours in cooler boxes with dry ice or ice packs to keep them frozen. 
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Samples were stored at -20°C until analysis. For each sample the flow rate of the sewage 
stream (L/day) was recorded. 
 
2.3 Extraction and analysis 
Before solid phase extraction, samples were thawed in a warm bath, then filtered to 
remove suspended particulate matter through 1.6 µm GF/A glass microfiber filters and 0.45 
µm mixed cellulose membrane filters from Whatman (Kent, UK). Then 3 mL of filtered 
wastewater were spiked with labeled internal standards (20 ng of caffeine-13C3 and 200 ng 
1,7-dimethyluric acid-d3) and, if necessary, the pH was adjusted to 6.0-7.5 with 12% HCl 
(v/v). Samples were loaded on Oasis HLB cartridges (3 mL, 60 mg), previously conditioned 
with 6 mL of MeOH and 3 mL of water. Cartridges were vacuum-dried for 10 minutes, 
wrapped in aluminum foil and immediately stored at -20 °C. For analysis, cartridges were 
eluted with 2 mL of methanol and the extract was evaporated to dryness under a nitrogen 
stream. Dry residues were redissolved in 100 µL MeOH-ultrapure water (20:80, v/v), 
centrifuged and transferred into glass vials for instrumental analysis. One µL of the final 
extract was injected into the liquid chromatography coupled to tandem mass spectrometry 
system (LC–MS/MS). The analyses were done by high-performance liquid chromatography 
(1200 Series pumps system, Agilent Technologies, CA) coupled to a triple quadrupole mass 
spectrometer (AB SCIEX QqQ 5500, Ontario, Canada). Samples were analysed using the 
positive electrospray ionization mode. Experimental conditions and detailed analytical 
conditions are described in Table S3 and S4 and in more detail in Senta et al., 2015. 
 
2.4. Daily mass loads and back-calculation of consumption 
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The daily mass loads (g/day) of the selected analytes were calculated multiplying the 
measured concentrations of caffeine and metabolites (ng/L) by the daily flow rate of 
wastewater (L/day) at the entry of each WWTP. 
Caffeine consumption was back-calculated using the approach proposed for illicit 
drugs by Zuccato et al., 2008. Specific correction factors were developed taking into account 
the percentage of urinary excretion of each metabolite and the molar mass ratio of the parent 
compound to the metabolite. All the pharmacokinetic studies accessible in the literature which 
reported data on the human urinary excretion of caffeine after oral administration (eight in all, 
see Supplemental Information) were reviewed to develop a specific correction factor for 
back-calculating caffeine intake by the population. The mean percentage of excretion of 
caffeine and its metabolites was calculated by weighting the number of subjects in each study. 
The total uncertainty related to the back-calculation procedure was evaluated as the standard 
deviation (SD) of the mean percentage of excretion (Table 1). This method had been 
previously proposed for refining the correction factors of the most used illicit drugs 
(Castiglioni et al., 2013; Gracia-Lor et al., 2016). 
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Table 1. Metabolic profiles of caffeine and its main metabolites in human urine (from pharmacokinetic studies and spot urine analysis) and from 
the levels measured in wastewater. 
Compound 
Mean excretion (%) from 
pharmacokinetic studies 
(SD) 
Geometric mean from spot 
urine analysis (95%CI) (2466 
subjects)a 
Mean excretion (%) from 
wastewater analysis (SD) 
 (70 samples) 
caffeine (1,3,7-trimethylxanthine) 1.7 (1.0) 1.81 (1.57-2.08) 20.9 (6.0) 
paraxanthine (1,7-dimethylxanthine) 4.6 (1.4) 7.47 (6.73-8.29) 22.1 (4.0) 
1-methylxanthine 10.0 (3.4) 17.1 (15.4-19.0) 15.8 (3.5) 
7-methylxanthine 3.1 (1.2) 31.4 (28.6-34.3) 24.9 (6.4) 
1-methyluric acid 16.5 (6.2) 39.4 (35.8-43.4) 4.7 (1.1) 
1,7-dimethyluric acid 6.7 (2.3) 12.2 (11.0-13.6) 11.6 (2.0) 
theophylline (1,3-dimethylxanthine) 0.6 (0.4) 0.872 (0.796-0.955) Not analyzed 
theobromine (3,7-dimethylxanthine) 1.5 (1.3) 12.4 (11.4-13.5) Not analyzed 
1,3-dimethyluric acid 1.6 (0.7) 3.51 (3.17-3.89) Not analyzed 
3,7-dimethyluric acid 0.2 (0.4) 0.784 (0.714-0.861) Not analyzed 
3-methylxanthine 2.0 (1.1) 19.2 (17.5-21.0) Not analyzed 
 
aData taken from Rybak et al., 2014 
 
11 
 
3. RESULTS AND DISCUSSION 
3.1 Caffeine biomarkers for back-calculation 
Selecting a substance as a biomarker is not easy to achieve as it must have specific 
characteristics (Gracia-Lor et al., 2016): i) be excreted in measurable quantities in wastewater; 
ii) be released to sewers exclusively from human excretion; iii) be unique to human 
metabolism to ensure that it comes only from human excretion and not from exogenous 
sources; iv) have low adsorption for suspended particulate; v) be stable in wastewater during 
in-sewer transport, and during storage and analysis. 
Each substance for this investigation was tested as a suitable biomarker of caffeine 
consumption as described above. Caffeine itself is not a good candidate because it comes not 
only from coffee but also from other sources. Caffeine metabolites too may originate from 
other naturally occurring alkaloids with similar structures, such as theobromine and 
theophylline, which themselves are also caffeine metabolites (Figure 1). Theobromine is 
present in cocoa beans (and subsequently in chocolate), tea leaves and cola beans. 
Theophylline is present in tea leaves in small amounts but is also used medically, for instance 
for asthma and other lung diseases (Senchina et al., 2014). Specifically, among five caffeine 
metabolites studied, 1-methylxanthine and 1-methyluric acid are also metabolites of 
theophylline, while 7-methylxanthine is the major metabolite of theobromine. Paraxanthine 
and 1,7-dimethyluric acid however, are exclusively metabolites of caffeine (Figure 1). Thus, 
they are potentially the most suitable biomarkers to back-calculate the amount of caffeine 
consumed, i.e. the consumption of all products containing caffeine (coffee, chocolate, tea, 
etc). As they come only from human excretion and not from exogenous sources, their 
presence can play an important role in identifying fresh water or ground water contaminated 
by sewage. 
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Figure 1. Metabolic pathway of caffeine in humans 
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3.2 Metabolic profiles in wastewater and in human urine 
According to the human urinary excretion profile of caffeine, the mass loads of 1-
methyluric acid should be the highest, followed by 1-methylxanthine, 1,7-dimethyluric acid, 
paraxanthine, 7-methylxanthine  and finally, caffeine (Table 1). However, the quantitative 
profiles of caffeine and the metabolites calculated from wastewater analysis did not 
completely agree with the human excretion profile. The mass loads (mean of the ten cities) 
decreased as follows: 7-methylxanthine > paraxanthine > caffeine > 1-methylxanthine > 1,7-
dimethyluric acid > 1-methyluric acid (Figure 2). Hence, there are large differences from the 
human excretion profile of caffeine. We therefore included supplementary data from spot 
urine analysis in our comparison (Table 1). These percentages (geometric mean, 95% CI) 
were obtained from Rybak et al., 2014, who recently measured caffeine and 14 metabolites in 
more than 2000 urine samples. We calculated also the percentages of excretion using the 
concentrations measured in wastewater in the ten European cities (Table 1). Each metabolite 
is reported as a percentage of the sum of the levels of metabolites plus caffeine measured in 
wastewater, following the procedure employed by Castiglioni et al., 2011 to calculate the 
metabolic profile of cocaine in wastewater and in human urine. The excretion profiles of 
caffeine and its metabolites were calculated using median values because of the high 
variability of the concentrations.  
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Figure 2. Normalized mass loads (g/day/1000 inhabitants) of caffeine and its metabolites in 
ten European cities in March 2015 and April 2015 (Porto). Means ± standard deviation (SD) 
of seven-day samples (only the upper limit of the SD bar is shown). 
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Data from wastewater could be reasonably compared with the profiles in spot urine 
samples, since they indicate respectively the profiles of excretion from an entire community 
and from single individuals. Percentages were comparable for 1-methylxanthine and 7-
methylxanthine acid in wastewater and spot urine samples, but higher than in 
pharmacokinetic studies (Table 1). This can be easily explained by the fact that they are also 
metabolites of theophylline and theobromine respectively. The percentage of caffeine in 
wastewater (21%) was much higher than expected from spot urine analysis and 
pharmacokinetic studies (1.8% and 1.7%). There might therefore be other sources of caffeine 
contributing to the total amount in wastewater (e.g., coffee grounds that are disposed down of 
the sink drain, disposal of coffee that was not drunk or improper disposal of caffeine for 
pharmacological use). In contrast, for 1-methyluric acid the percentage in wastewater was 
lower than in urine and in pharmacokinetic studies. A possible explanation could be 
degradation of this compound in wastewater such as in-sewer, during transport or during 
storage. This should be verified by in-sewer experiments and additional modeling studies.  
Some differences were observed for paraxanthine (22.1% of the total in wastewater, 
4.6% in pharmacokinetic studies and 7.5% in spot urine samples); however for 1,7-
dimethyluric acid the results were comparable (approximately 12% of the measured 
concentrations in wastewater and in spot urine samples, and 4.3-12.6% of the administered 
dose in pharmacokinetic studies (see data in SI)). Taking to account of all these 
considerations, 1,7-dimethyluric acid seemed to be the most suitable biomarker for the back-
calculation of caffeine. The mean percentage of excretion of this metabolite weighted by the 
number of subjects in each study (6.7%) and the 1,7-dimethyluric acid/caffeine molecular 
mass ratio were used to obtain the correction factor (CF), according to the following equation: 
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where Mw is the molecular weight and the mean excretion is the weighted mean of the 
percentage of excretion of  the target metabolite. 
 
3.3 Estimation of caffeine consumption 
Using the proposed correction factor, caffeine consumption (in mg/day/person) in 
each city was calculated based on the wastewater measurements of 1,7-dimethyluric acid. The 
mean daily consumption of caffeine per capita ranged from 263 mg/day/person in Zurich to 
87 mg/day/person in Milan (Table 2). These data match the mean daily caffeine intake in 
Europe of around 300 mg/day/person estimated by the European Food Safety Authority 
(means range from 37 to 320 mg/day/person estimated from individual surveys for adults 
between 18 and 64 years) (European Food Safety Authority (EFSA), 2015). 
For a more accurate comparison, we compared our wastewater analysis data to the 
amount of coffee consumed per country per capita (per person on average), which reflects the 
imports of coffee by each country, according to the International Coffee Organization (ICO) 
(International Coffee Organization (ICO), 2015). We converted the per capita consumption 
(in kg/person) of coffee to the daily intake of caffeine per person considering that dry coffee 
beans contain about 1.1% of caffeine in Arabica and about 2.2% in Robusta coffee. In 2015, 
around 60% of the coffee exported was Arabica (“International Coffee Organization,” 2015), 
but the proportion can change from country to country. For instance, according to Garattini, 
1993, consumer countries can be classified in three levels: (a) where consumption of Arabica 
accounts for more than 70% (Switzerland and Northern European countries, i.e. Norway and 
Denmark); (b) where consumption of Arabica is around 50% (Italy, the Netherlands, Belgium 
and the UK); (c) where consumption of Robusta predominates (Spain and Portugal) (Table 
2). In addition, the amount of caffeine extracted varies with the preparation method, ranging 
from 75% in boiled coffee to nearly 100% in filtered coffee. To estimate the amount of 
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caffeine in the coffee we took 1.1% for countries classified in group (a), 1.6% (i.e. mean 
caffeine content in Arabica and in Robusta) for countries belonging to group (b) and 2.2% for 
countries in group (c). In all cases, we assumed 95% extraction efficiency, as previously 
proposed (Fredholm et al., 1999).  
For four cities (Oslo, Copenhagen, Zurich and Brussels), the difference was 20% or 
less. The amounts for Castellón, Utrecht, Milan, Lugano and Porto estimated from wastewater 
analysis were lower than indicated by the coffee trade figures, and higher in Bristol. This 
might be due to different factors: first of all, we compared data from whole country with data 
in a specific city, while population habits might be different. This was the case for Zurich and 
Lugano, two Swiss cities: a 20% difference was obtained for Zurich (410,000 inhabitants), 
whilst it was around 50% for Lugano (100,000 inhabitants). Secondly, we compared annual 
coffee trade figures with caffeine estimated through wastewater analysis in one week. Finally, 
data obtained through back-calculation refer to the amount of caffeine consumed in all 
products that contain relatively large amounts such as coffee, chocolate, soft drinks and 
medications. Thus, larger amounts of caffeine estimated through the wastewater analysis in 
Zurich, Copenhagen, and especially in Bristol, might be due to higher consumption of other 
products in those countries. Switzerland is in fact the country with the highest per capita 
consumption of chocolate, and the UK is also among the countries with the highest 
consumption, according to different sources (Statista, 2015; Target Map, 2015)). Another 
reason might be the fact that the caffeine content of coffee in the UK is higher than in other 
countries (Barone and Roberts, 1996). Furthermore, tea containing around 3% of caffeine is 
the most popular drink in the UK today, and contributes to caffeine consumption. In five 
cities, the difference was of at least 50%. 
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Table 2. Caffeine consumption estimated from wastewater analysis and using coffee trade data for the countries investigated. The difference was 
calculated between the estimates from international statistics and from wastewater analysis. 
 Caffeine from 
wastewater analysis Caffeine from international statistics* Difference (%) Cities investigated 
(country) 
mg caffeine/day/person 
(SD) Kg coffee/year/person* 
Type of coffee mostly 
consumeda mg caffeine/day/person 
Bristol (UK) 190 (37) 3.3 50% Arabica-50% Robusta 137 -38 
Brussels (Belgium) 162 (15) 4.3 50% Arabica-50% Robusta 179 16 
Castellón (Spain) 122 (28) 4.5 Robusta 258 53 
Copenhagen (Denmark) 229 (19) 6.9 Arabica 198 -16 
Lugano (Switzerland) 97 (16) 7.6 Arabica 218 55 
Milan (Italy) 86 (18) 5.6 50% Arabica-50% Robusta 233 63 
Oslo (Norway)  211 (21) 8.7 Arabica 249 15 
Porto (Portugal) 121 (27) 4.8 Robusta 275 56 
Utrecht (The Netherlands) 107 (28) 5.3 50% Arabica-50% Robusta 221 51 
Zurich (Switzerland) 263 (23) 7.6 Arabica 218 -20 
 
*Source: International Coffee Organization (ICO), 2015 (http://www.ico.org/coffee-trade-statistics-infographics.asp) 
a(Garattini, 1993) 
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The aim of the comparison between the amount of caffeine consumed, estimated from 
the wastewater analysis, and coffee consumption figures from international trade was mainly 
to check whether the proposed metabolite was a suitable biomarker of consumption. The 
results indicate that 1,7-dimethyluric acid can be used for this purpose, although additional 
studies are needed to validate this approach, including more extensive wastewater sampling 
campaigns in different countries.  
Additional information on the current proportions (percentages) of commercial 
varieties of coffee consumed in each country is also needed for more accurate comparisons. 
There are some differences between coffee consumption data, in terms of the amount 
consumed in each country per capita, published by different sources (for instance, between the 
ICO (International Coffee Organization (ICO), 2015) which is based on coffee imports and 
exports and Euromonitor International (Caffeine Informer, 2016), which deals with local 
business information). This is another factor that may influence the accuracy of a data 
comparison.  
Additionally, only eight studies could be found dealing with the human excretion of 
caffeine, so more pharmacological studies are essential to improve the reliability of urinary 
excretion profiles and the correction factors used to back-calculate caffeine consumption. At 
present, these studies are scarce and most are quite old and based on a small number of 
subjects (Gracia-Lor et al., 2016).   
 
4. CONCLUSIONS 
Profiles of caffeine metabolites in wastewater reasonably matched the profiles in spot 
urine samples suggesting that the analysis in wastewater might reflect the collective 
consumption of caffeine-containing products.  
We selected 1,7-dimethyluric acid for caffeine back-calculation because it is an 
exclusive human metabolite of caffeine and so it is only produced by consumption of products 
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containing caffeine (i.e. coffee, tea, chocolate, etc.). The percentage of its excretion from 
pharmacokinetic studies is similar to the profiles found in urine and in wastewater (estimated 
from 70 influent wastewater samples collected in ten European cities). The mean daily 
consumption of caffeine per capita, estimated from wastewater analysis using the correction 
factor proposed, matched the mean daily caffeine intake (from 37 to 320 mg/day/person 
estimated from individual surveys for adults 18-64 years old). In four cities a good correlation 
was seen between wastewater analysis and the amount of coffee consumed in the country per 
capita. Several factors might explain discrepancies in the other six cities. For instance the 
estimation of coffee consumption on the basis of the imports of coffee by each country is 
influenced by many uncertainties, so it is hard to estimate the consumption of other 
commodities contributing to caffeine intake. Furthermore, the correction factor may be 
imprecise due to uncertainties in the metabolism studies in the literature. Thus, new studies 
are needed about the metabolism and urinary excretion of caffeine in realistic intake amounts. 
Stability tests of biomarkers in sewers are also needed.  
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Table S1. Excretory profile of caffeine and its metabolites 
 
Caffeine (1,3,7-trimethylxanthine) 
References Dose Subjects treated Duration (h) 
Caffeine excretion 
(%) 
SD 
(Latini et al., 1981)  5 mg/kg 4 72 1.8  
(Dan-Shya et al., 
1983)  
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 3.7 1 
(Callahan et al., 
1982)  
5 mg/kg (14C-labeled caffeine) 10 48 1.1 0.59 
(Callahan et al., 
1983)  
5 mg/kg (2-14C)caffeine 
4 males 
4 females oral contraceptives 
4 ovulating females 
96 
1.46 
2.61 
1.33 
0.4 
1.19 
0.45 
(Blanchard et al., 
1985)  
5 mg/kg 
5 (elderly) 
7 (young) 
24 
1.93 
2.35 
0.57 
2.05 
(Scott et al., 1986)  
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
3.3 
2.0 
1.4 
1.1 
(Carrillo and Benitez, 
1994)  
300 mg 107 24 1.4 0.07 
 
 
Paraxanthine (1,7-dimethylxanthine) 
References Dose  Subjects treated Duration (h) 
Paraxanthine 
excretion (%) 
SD 
(Latini et al., 1981) 5 mg/kg 4 72 5  
(Dan-Shya et al., 
1983) 
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 
60 7.1 1.7 
(Callahan et al., 
1982) 
5 mg/kg (14C-labeled caffeine) 10 48 5.7 1.64 
(Callahan et al., 5 mg/kg (2-14C)caffeine 4 males 96 5.39 1.63 
5 
 
1983) 4 females oral contraceptives 
4 ovulating females 
5.49 
3.45 
0.26 
0.18 
(Grant et al., 1983) 300 mg 68 24 4.8 2.4 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
 
24 
3.37 
3.49 
1.47 
1.87 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
5.8 
4.7 
1.1 
0.9 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 4.08 0.18 
 
 
1-methylxanthine 
References Dose  Subjects treated Duration (h) 
1-methylxanthine 
excretion (%) 
SD 
(Latini et al., 1981)  5 mg/kg 4 72 16  
(Dan-Shya et al., 
1983)  
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 10 3 
(Callahan et al., 
1982)  
5 mg/kg (14C-labeled caffeine) 10 48 16.31 3.76 
(Callahan et al., 
1983)  
5 mg/kg (2-14C)caffeine 
4 males 
4 females oral contraceptives 
4 ovulating females 
96 
14.88 
9.32 
12.28 
1.94 
1.44 
4.75 
(Grant et al., 1983)  300 mg 68 24 10.1 4.1 
(Blanchard et al., 
1985)  
5 mg/kg 
5 (elderly) 
7 (young) 
24 
8.9 
9.48 
5.4 
3.7 
(Scott et al., 1986)  
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
7.3 
11.4 
3.4 
2.1 
(Carrillo and Benitez, 
1994)  300 mg 107 24 9.13 0.4 
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7-methylxanthine 
References Dose Subjects treated Duration (h) 
7-methylxanthine 
excretion (%) 
SD 
(Latini et al., 1981)  5 mg/kg 4 72 8.5  
(Dan-Shya et al., 
1983)  
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 
60 4 1.6 
(Callahan et al., 
1983) 
5 mg/kg (2-14C)caffeine 
4 males 
4 females oral contraceptives 
4 ovulating females 
96 
1.84 
1.81 
2.17 
0.5 
0.25 
0.45 
(Grant et al., 1983) 300 mg 68 24 2.5 1.4 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
2.32 
2.4 
1.18 
1.45 
(Scott et al., 1986)  
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
5 
4 
2.6 
0.3 
(Carrillo and Benitez, 
1994)  
300 mg 107 24 3.11 0.21 
 
 
1-methyluric acid 
References Dose  Subjects treated Duration (h) 
1-methyluric acid 
excretion (%) 
SD 
(Latini et al., 1981) 5 mg/kg 4 72 51  
(Dan-Shya et al., 
1983) 
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 21 8 
(Callahan et al., 
1982) 
5 mg/kg (14C-labeled caffeine) 10 48 25.55 5.2 
(Callahan et al., 
1983) 
5 mg/kg (2-14C)caffeine 
4 males 
4 females oral contraceptives 
4 ovulating females 
96 
19.89 
11.06 
16.14 
3.9 
1.95 
4.79 
(Grant et al., 1983) 300 mg 68 24 11.8 5 
7 
 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
38.12 
22.05 
14.23 
4.69 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
9.4 
19.5 
3.7 
5.3 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 16.49 0.84 
 
 
1,7-dimethyluric acid 
References Dose  Subjects treated Duration (h) 
1,7-dimethyluric acid 
excretion (%) 
SD 
(Latini et al., 1981) 5 mg/kg 4 72 8.5  
(Dan-Shya et al., 
1983) 
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 7.3 1 
(Callahan et al., 
1982) 
5 mg/kg (14C-labeled caffeine) 10 48 4.32 1.64 
(Callahan et al., 
1983) 
5 mg/kg (2-14C)caffeine 
4 males 
4 females oral contraceptives 
4 ovulating females 
96 
6.19 
9 
6.05 
3.31 
2.04 
2.63 
(Grant et al., 1983) 300 mg 68 24 6 1.9 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
12.56 
7.81 
1.99 
3.36 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
9.3 
7.2 
2.9 
2.1 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 6.57 0.22 
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Theophylline (1,3-dimethylxanthine) 
References Dose  Subjects treated Duration (h) 
Theophylline 
excretion (%) 
SD 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
0.48 
0.77 
0.31 
0.69 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
1.6 
0.8 
0.5 
0.4 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 0.5 0.04 
 
 
Theobromine (3,7-dimethylxanthine) 
References Dose  Subjects treated Duration (h) 
Theobromine 
excretion (%) 
SD 
(Latini et al., 1981) 5 mg/kg 4 72 3.2  
(Callahan et al., 
1982) 
5 mg/kg (14C-labeled caffeine) 10 48 1.57 0.46 
(Callahan et al., 
1983) 
5 mg/kg (2-14C)caffeine 
4 males 
4 females oral contraceptives 
4 ovulating females 
96 
1.21 
1.18 
0.92 
0.29 
0.23 
0.54 
(Grant et al., 1983) 300 mg 68 24 1.1 0.6 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
1.22 
2.04 
0.79 
1.96 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
4.3 
1.4 
3.4 
0.6 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 1.28 0.1 
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1,3-dimethyluric acid 
References Dose  Subjects treated Duration (h) 
1,3-dimethyluric 
acid excretion (%) 
SD 
(Latini et al., 1981) 5 mg/kg 4 72 4  
(Dan-Shya et al., 
1983) 
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 2.9 1 
(Callahan et al., 
1982) 
5 mg/kg (14C-labeled caffeine) 10 48 2.05 0.31 
(Grant et al., 1983) 300 mg 68 24 1.2 0.4 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
3.37 
2.73 
0.89 
0.86 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
2.6 
1.6 
0.9 
0.5 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 1.31 0.04 
 
 
3,7-dimethyluric acid 
References Dose Subjects treated Duration (h) 
3,7-dimethyluric 
acid excretion (%) 
SD 
(Dan-Shya et al., 
1983) 
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 1.2 0.5 
(Carrillo and Benitez, 
1994) 
300 mg 98 24 0.16 0.13 
 
 
3-methylxanthine 
References Dose Subjects treated Duration (h) 
3-methylxanthine 
excretion (%) 
SD 
(Latini et al., 1981) 5 mg/kg 4 72 3.5  
10 
 
(Dan-Shya et al., 
1983) 
Theophylline (7.5 mg/kg) and 
caffeine (7.5 mg/kg) 2 weeks later 
6 60 2.3 0.3 
(Callahan et al., 
1982) 
5 mg/kg (14C-labeled caffeine) 10 48 
2.09 
1.98 
2.12 
0.56 
0.24 
0.51 
(Grant et al., 1983) 300 mg 68 24 1.5 0.7 
(Blanchard et al., 
1985) 
5 mg/kg 
5 (elderly) 
7 (young) 
24 
0.94 
1.93 
0.51 
0.91 
(Scott et al., 1986) 
123-369 mg 
300-750 mg 
15 pregnant 
9 female 
24 
5.6 
2.6 
3.2 
0.7 
(Carrillo and Benitez, 
1994) 
300 mg 107 24 1.7 0.11 
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Table S2. Main characteristics of the wastewater treatment plants (WWTPs) investigated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WWTPs investigated 
(country) 
Mean daily flow rate 
(m3/day) Population served by WWTP Sampling dates (2015) 
Bristol (UK) 209,289 886,650 10 – 16 March 
Brussels (Belgium) 251,830 954,000 18 – 24 March 
Castellón (Spain) 42,372 180,000 25 – 31 March 
Copenhagen (Denmark) 144,558 530,000 10 – 16 March 
Lugano (Switzerland) 44,386 103,560 25 – 31 March 
Milan (Italy) 437,726 1,100,000 10 – 16 March 
Oslo (Norway) 276,235 580,000 11 – 17 March 
Porto (Portugal) 31,560 150,000 23 – 29 April 
Utrecht (The Netherlands) 46,743 300,000 4 – 10 March 
Zurich (Switzerland) 180,088 410,000 18 – 24 March 
12 
 
Table S3. Precursor and products ions of the analyzed compounds with the associated collision energies 
 
Compound 
Precursor ion 
(m/z) 
Product ion 1 (m/z) and 
collision energy (eV) 
Product ion 2 (m/z) and 
collision energy (eV) 
caffeine 195.1 138 (25) 110 (30) 
caffeine-3C13 198.1 140 (25) - 
Paraxanthine (1,7-dimethylxanthine) 181.1 124 (26) 96 (32) 
1-methylxanthine 167.1 110 (25) 82 (33) 
7-methylxanthine 167.1 124 (24) 150 (24) 
1-methyluric acid 182.1 70.1 (30 ) 126.0 (24 ) 
1,7-dimethyluric acid 197.1 140.1 (25 ) 69.1 (35 ) 
1,7-dimethyluric acid-d3 200.1 140.1 (25 ) - 
 
 
 
13 
 
Table S4. Linearities, recoveries, repeatability and quantification limits 
 
Compound 
Linearity 
range (ng/mL) 
Coefficient of 
correlation (r2) 
Recovery 
(%) 
Repeatability 
RSD (%) 
MQL 
(ng/L) 
Caffeine* 0-600 0.9989 88 12 3.6 
Paraxanthine (1,7-dimethylxanthine)* 0-600 0.9996 76 5 6.6 
1-methylxanthine* 0-600 0.9996 72 14 6.1 
7-methylxanthine* 0-600 0.9999 64 10 28.5 
1-methyluric acid 0-600 0.9988 68 14 220 
1,7-dimethyluric acid 0-600 0.9990 87 4 185 
 
*(Senta et al., 2015) 
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